CONTACT

E-mail: cvt@bkhlaw.dk

Mobile: +45 26 22 72 22

       View LinkedIn Profile

INDUSTRIES
Healthcare – Pharma & Life Science 
Technology
Retail and e-commerce

CHRISTIAN VINDING THOMSEN
PARTNER, ATTORNEY-AT-LAW

EXPERTICES

(M&A) Mergers and Acquisitions

Capital Markets

Compliance and internal investigations 

Intellectual property rights 

E-commerce, Marketing and Consumer Law

PREVIOUSLY PARTNER/LAWYER WITH:

  • Bech Bruun Law Firm

 

EXECUTIVE EDUCATION THROUGH:

  • University of Copenhagen, Master of Laws (cand.jur.)

  • Attorney-at-law 

  • The Wharton School of the University of Pennsylvania, Bech-Bruun Strategic Partner Program

 

SELECTED BOARD AND EXECUTIVE POSITIONS: 

  • Chairman of the Board of Directors, KT Stålindustri A/S 

  • Member of the Board of Directors, Scandion Oncology A/S 

  • Member of the Board of Directors, Reponex Pharmaceuticals A/S 

  • Member of the Board of Directors, Repoceuticals A/S 

  • Member of the Board of Directors, AKI Therapeutics ApS 

  • Member of the Board of Directors, Danish Life Science Law Association 

  • Vice chairman of the Board of Directors, Medicoindustriens Udredningspanel 

RECOMMENDATIONS: 

  • Christian has been recommended by Chambers (Global), Chambers (Europe), Legal 500 and Who's Who Legal. 

  • Legal 500 (2021): "Christian Vinding Thomsen is highly recognized as a leading life sciences specialist in Denmark. His industry knowledge is second to none and his ability to combine legal and technical skills with a focused commercial knowledge about the industry has made him our preferred advisor for many years now." 

  • Chambers Global (2021): Christian Vinding Thomsen primarily advises clients in the life sciences and healthcare sectors. He is recognised for his regulatory and compliance activities. Clients state that he is "knowledgeable, proactive, flexible, attentive and accessible." 

  • Chambers Europe (2021): Christian Vinding Thomsen assists life sciences entities with IP-related topics. He is highlighted for his knowledge of the pharmaceutical sector.